The White House is preparing a major overhaul of the National Institutes of Health grant review process, centralizing the final project approval and funding decision-making power — traditionally held by NIH’s internal peer-review system — in the executive branch. The reform is viewed by the scientific, medical and public health communities as a fundamental break with NIH’s decades-long peer-review tradition and could further politicize research priorities, with far-reaching implications for biomedical research, rare disease initiatives and public health emergency response.

Event Details

Background and Latest Developments: According to The New York Times and other outlets, the White House is studying a systemic reform of the NIH grant review mechanism. The core idea is to shift away from the long-standing model in which external expert panels conduct peer review and determine project priorities and funding allocations, and instead concentrate the final decision-making layer in the executive branch or in politically appointed officials. NIH is the world’s largest biomedical research funder, with an annual budget on the order of tens of billions of dollars, supporting basic biology, clinical medicine, public health and translational research.

Current Mechanism and Reform Impact: NIH’s peer-review system is widely regarded as the gold standard for research funding. It draws on tens of thousands of external experts to independently evaluate the scientific value, methodology and potential impact of every proposal, largely insulating funding from political, regional or commercial interference. If the reform proceeds, project funding would no longer be determined solely by scientific merit but could be shaped by administration policy preferences, ideological leanings or even short-term political considerations.

Supporting View: Some administration officials and conservative think tanks argue the reform will strengthen accountability in NIH spending, better align research with national strategic priorities — such as rare diseases, children’s health and biosecurity threats — and address what they see as long-standing inefficiencies in cross-agency coordination and responsiveness to strategic national needs.

Opposing View: The American Association for the Advancement of Science, university presidents’ associations, rare disease research groups and multiple Nobel laureates have voiced strong opposition. They warn that the reform could trigger a major brain drain, weaken U.S. leadership in global biomedicine, and push NIH toward a highly politicized direction. Multiple public health experts note that NIH-funded research played a critical role in COVID-19, Ebola and HIV/AIDS response, and that politicization could undermine America’s ability to confront future public health crises.

Legal and Institutional Layer: The reform plan also faces multiple legal uncertainties. Final NIH funding authorization comes from annual congressional appropriations, and whether the White House can unilaterally change the grant approval mechanism without congressional authorization remains legally contested. Several senators have already announced plans to hold hearings, demanding the administration explain the scope, timeline and legal basis of the proposed reform.

Panoramic Perspective

The White House’s move to take control of NIH funding is, on the surface, an administrative process adjustment, but in substance it touches the core compact of the U.S. research governance system. The compact is: taxpayers fund science; scientists, through peer review, decide where the money goes; the executive branch sets macro policy and budget envelopes but does not intervene in individual scientific judgments. Once that compact is broken, funding allocation will inevitably be shaped by political cycles, ideology and short-term news cycles. From a global perspective, the NIH model has long served as a reference point for science funding systems worldwide; if the reform proceeds, it could shake international scientific trust in the U.S. research system and accelerate diversification of collaboration and talent pipelines into Europe and Asia. In the longer term, this contest over research autonomy is not only about where specific dollars flow, but about whether the United States can preserve its institutional advantages in next-generation fields such as biomedicine, synthetic biology and AI-assisted drug discovery.

Multi-Perspective Comparison

Administration Position: Holds that the current NIH peer-review mechanism is insufficiently efficient and that more direct political accountability is needed to channel research resources into administration-defined priority areas.

Scientific Community Position: Led by the American Association for the Advancement of Science, warns that the reform will damage research independence, trigger talent outflow and push research topics onto the ideological front line.

Medical Community Position: Multiple clinical medicine associations and rare-disease groups worry that the reform could weaken support for long-term, high-risk but potentially breakthrough basic research.

Congressional Position: Lawmakers from both parties have raised concerns, focused on whether congressional authorization is required, the impact on the biomedical industrial chain, and future public health emergency capacity.

International Scientific Position: European and Asian research institutions are already assessing the reform’s implications for collaboration risk and talent flows, with some drafting targeted talent attraction plans.

编辑：GoodInfo全球资讯组